The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study

Clinical and Translational Gastroenterology

Volumn 10, Issue 4, 2019, Pages

  Holster, Savanne ^a   Lindqvist, Carl Mårten ^a   Repsilber, Dirk ^a   Salonen, Anne ^b   De Vos, Willem M ^b,c   Konig, Julia ^a   Brummer, Robert J ^a  

^a Örebro University   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOPERAMIDE;

ADULT; ALLOGENIC FECAL MICROBIOTA TRANSFER; ARTICLE; AUTOLOGOUS FECAL MICROBIOTA TRANSFER; BLOATING; CLINICAL ARTICLE; COLON FLORA; COLON LAVAGE; COLONOSCOPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FATIGUE; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL PAIN; HEADACHE; HEMORRHOID; HOT FLUSH; HUMAN; IRRITABLE COLON; MALE; MICROBIAL DIVERSITY; NAUSEA; NONHUMAN; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPECIES COMPOSITION; THIRST; TREATMENT OUTCOME; VISCERAL SENSITIVITY; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; COMPLICATION; FECES; IMMUNOLOGY; INTESTINE FLORA; MICROBIOLOGY; MIDDLE AGED; PAIN MEASUREMENT; PROCEDURES; VISCERAL PAIN;

ADULT; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VISCERAL PAIN;

EID: 85065348616     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.14309/ctg.0000000000000034     Document Type: Article

References (39)

1. Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: The efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017;46(5):479–93.
2. König J, Siebenhaar A, Högenauer C, et al. Consensus report: Faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther 2017;45(2):222–39.
3. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149(1):102–9 e106.
4. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial. Lancet 2017;389(10075):1218–28.
5. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149(1):110–8.e114.
6. Kootte RS, Levin E, Salojarvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 2017;26(4):611–9.e616.
7. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143(4):913–6.e917.
8. Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018;3(1):17–24.
9. Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: Results from a randomised, double-blind placebo-controlled study. Gut 2018;67:2107–15.
10. Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep 2015;5:12693.
11. Hamer HM, Jonkers D, Venema K, et al. Review article: The role of butyrate on colonic function. Aliment Pharmacol Ther 2008;27(2):104–19.
12. Vanhoutvin SA, Troost FJ, Kilkens TO, et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009;21(9):952–e976.
13. Hamer HM, Jonkers DM, Vanhoutvin SA, et al. Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr 2010;29(6):738–44.
14. Chang L. From Rome to los Angeles-the Rome III criteria for the functional GI disorders. Gastroenterology 2006;130:1480–91.
15. Louis P, Flint HJ. Development of a semiquantitative degenerate real-time pcr-based assay for estimation of numbers of butyryl-coenzyme A (CoA) CoA transferase genes in complex bacterial samples. Appl Environ Microbiol 2007;73(6):2009–12.
16. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9(12):1044–9.
17. Satokari R, Mattila E, Kainulainen V, et al. Editorial: A simple faecal preparation for faecal microbiota transplantation—Authors' reply. Aliment Pharmacol Ther 2015;41(3):321.
18. Wiklund IK, Fullerton S, Hawkey CJ, et al. An irritable bowel syndrome-specific symptom questionnaire: Development and validation. Scand J Gastroenterol 2003;38(9):947–54.
19. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11(2):395–402.
20. Ware JE Jr, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: Results from the IQOLA project. Int Qual Life Assess J Clin Epidemiol 1998;51(11):1167–70.
21. Wong E, Guyatt GH, Cook DJ, et al. Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur J Surg Suppl 1998 (583):50–6.
22. Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J 1986;292(6516):344.
23. Rajilic-Stojanovic M, Heilig HG, Molenaar D, et al. Development and application of the human intestinal tract chip, a phylogenetic microarray: Analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol 2009;11(7):1736–51.
24. Kilkens TO, Honig A, van Nieuwenhoven MA, et al. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004;53(12):1794–800.
25. Salonen A, Nikkilä J, Jalanka-Tuovinen J, et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods 2010;81(2):127–34.
26. Claesson MJ, O'Sullivan O, Wang Q, et al. Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One 2009;4(8):e6669.
27. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011;473(7346):174–80.
28. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407–15.
29. Fisher RA, Corbet AS, Williams CB. The relation between the number of species and the number of individuals in a random sample of animal population. J Anim Ecol 1943;12(1):42–58.
30. Hurlbert SH. The nonconcept of species diversity: A critique and Alternative parameters. Ecology 1971;52(4):577–86.
31. Team RC. R: A Language and Environment for Statistical Computing. 2016 (https://www.R-project.org/). Accessed on October 22, 2017.
32. Jalanka J, Salonen A, Salojärvi J, et al. Effects of bowel cleansing on the intestinal microbiota. Gut 2015;64(10):1562–8.
33. Ponnusamy K, Choi JN, Kim J, et al. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 2011;60(Pt 6):817–27.
34. Rangel I, Sundin J, Fuentes S, et al. The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects. Aliment Pharmacol Ther 2015;42(10):1211–21.
35. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016;352(6285):565–9.
36. Fuentes S, Rossen NG, van der Spek MJ, et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME J 2017;11(8):1877–89.
37. Vital M, Karch A, Pieper DH. Colonic butyrate-producing communities in humans: An overview using omics data. mSystems 2017;2(6):e00130–17.
38. Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007;19(1 Suppl):62–88.
39. Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013;25(4):e272–282